02285nas a2200193   4500008003900000245014700039210006900186260000900255300001400264490000700278520155700285653002601842653002401868653002301892653001801915653001501933100009501948856004802043       2010                          d00aLiver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature0 aLiver transplant from AntiHBcpositive HBsAgnegative donor into H  c2010  a735 - 7460 v243 aAbstract: Introduction:  After liver transplant (LT) from Anti-HBc+/HBsAg− donors into HBsAg− recipients, transmission of hepatitis B virus (HBV) may occur (de novo HBV infection). This study analyzes the incidence of de novo HBV infection in HBsAg− recipients of Anti-HBc+/HBsAg− LT with respect to: (i) the recipients’ HBV serology and (ii) the type of preventive therapy adopted. Methods:  A systematic review of the literature using the electronic database Medline. Results:  Five hundred and fifty-two LT in 36 articles were selected. Lamivudine, Hepatitis B immune globulin (HBIG), revaccination, and combined therapies were employed in multiple strategies as preventive interventions. Naïve recipients had a high risk of de novo HBV infection, with smaller incidences when HBIG and lamivudine were used, either alone or in association. Vaccinated recipients or those with isolated hepatitis B core antibodies (Anti-HBc) and previous HBV infection had lower risks of viral transmission, additionally reduced by any prophylaxis adoption. Discussion:  LT from Anti-HBc+/HBsAg− donors into HBsAg− recipients is apparently safe, as long as the recipient is vaccinated or presents an isolated Anti-HBc or previous HBV infection and some prophylaxis is employed. Currently lamivudine seems the best alternative; other nucleoside analogs and revaccination strategies should be considered in future studies. Follow-up and preventive therapies should be maintained for five yr or preferably throughout the recipients’ life span.10a* expanded donor pool10a* hepatitis B virus10a* liver transplant10a* prophylaxis10a* serology1 aAvelino-Silva, D′Albuquerque LAC Bonazzi PR Song ATW Miraglia JL Brito Neves Abdala, A E  uhttps://www.notifylibrary.org/reference/108